IP Library Granted Patent US 8,673,843
Granted Patent B2
US 8,673,843 · App. 13/525,861 · Granted Mar 18, 2014

NMDA receptors modulators and uses thereof

Inventors: Joseph Moskal (Evanston, IL); M. Amin Khan (Evanston, IL)
Assignee: Northwestern University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,673,843
App. No.
13/525,861
Granted
Mar 18, 2014
Kind
B2
Abstract

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Claims (27)

1. A compound represented by:

wherein:

R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of hydrogen; halogen, C 1 -C 6 alkyl, and —OH;

R 5 is —CH 2 -phenyl;

X is —NH 2 ; and

pharmaceutically acceptable salts, stereoisomers, and hydrates thereof.

2. The compound of claim 1 represented by:

3. The compound of claim 1 represented by:

4. A pharmaceutical composition, comprising:

a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4 , suitable for oral administration.

6. The pharmaceutical composition of claim 4 , suitable for injection.

7. The compound of claim 1 represented by:

8. A compound represented by:

wherein:

R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of hydrogen; halogen, C 1 -C 6 alkyl, and —OH;

R 5 is —CH 2 -phenyl;

X is selected from the group consisting of —OH, —O—C 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), and —NH(C 1 -C 6 alkyl) 2 ; and

pharmaceutically acceptable salts, stereoisomers, and hydrates thereof.

9. The compound of claim 8 represented by:

wherein X is OH or NH 2 .

10. A compound represented by:

and pharmaceutically acceptable salts and hydrates thereof.

11. A pharmaceutical composition, comprising:

a therapeutically effective amount of a compound of claim 10 and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is suitable for oral administration.

12. A pharmaceutical composition, comprising:

a therapeutically effective amount of a compound of claim 10 and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is suitable for injection.

Assignments (5)
SECURITY INTEREST Recorded Dec 18, 2024
From: GATE NEUROSCIENCES, INC.
To: INNOVIVA TRC HOLDINGS LLC
Reel/Frame 069742/0846 →
SECURITY INTEREST Recorded Nov 6, 2023
From: GATE NEUROSCIENCES, INC.
To: INNOVIVA TRC HOLDINGS LLC
Reel/Frame 065473/0327 →
CONFIRMATORY ASSIGNMENT Recorded Nov 18, 2014
From: MOSKAL, JOSEPH; KHAN, M. AMIN
To: NORTHWESTERN UNIVERSITY
Reel/Frame 034283/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2014
From: KHAN, AMIN; MOSKAL, JOSEPH
To: NAUREX, INC.
Reel/Frame 032039/0672 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2014
From: NAUREX, INC.
To: NORTHWESTERN UNIVERSITY
Reel/Frame 032039/0978 →
Continuity (4)
Continuation In Part PCTUS2011024583 · Feb 11, 2011
Provisional Application 61550782 · Oct 24, 2011
Provisional Application 61303472 · Feb 11, 2010
Related Publication 20130035292A1 · Feb 7, 2013